- Low expression of KCNN3 may affect drug resistance in ovarian cancer
Xia Liu et al, 2018, Molecular Medicine Reports CrossRef - CXC and CC Chemokines as Angiogenic Modulators in Nonhaematological Tumors
Matteo Santoni et al, 2014, BioMed Research International CrossRef - Docetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression
Alexandra R. Harris et al, 2018, BMC Cancer CrossRef - SPARCL1 impedes trophoblast migration and invasion by down-regulating ERK phosphorylation and AP-1 production and altering EMT-related molecule expression
Xiaojing Liu et al, 2020, Placenta CrossRef - Emerging Roles for Ion Channels in Ovarian Cancer: Pathomechanisms and Pharmacological Treatment
Concetta Altamura et al, 2021, Cancers CrossRef - Upregulation of NEK2 is associated with drug resistance in ovarian cancer
XIA LIU et al, 2014, Oncology Reports CrossRef - Downregulation of transient receptor potential cation channel, subfamily C, member 1 contributes to drug resistance and high histological grade in ovarian cancer
XIA LIU et al, 2016, International Journal of Oncology CrossRef - Integrative genomic analyses of secreted protein acidic and rich in cysteine and its role in cancer prediction
BO WANG et al, 2014, Molecular Medicine Reports CrossRef - Discovery of microarray-identified genes associated with ovarian cancer progression
XIA LIU et al, 2015, International Journal of Oncology CrossRef - Chemokines driven ovarian cancer progression, metastasis and chemoresistance: Potential pharmacological targets for cancer therapy
Subhankar Bose et al, 2022, Seminars in Cancer Biology CrossRef - Lymphatic vasculature in ovarian cancer
Sarit Pal et al, 2023, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef - Downregulation of HNF1 homeobox B is associated with drug resistance in ovarian cancer
JIANCHAO LI et al, 2014, Oncology Reports CrossRef - Lipid metabolism and Calcium signaling in epithelial ovarian cancer
Sana Kouba et al, 2019, Cell Calcium CrossRef - An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy
Lishuang Qi et al, 2016, British Journal of Cancer CrossRef - Downregulation of tumor suppressor gene ribonuclease T2 and gametogenetin binding protein 2 is associated with drug resistance in ovarian cancer
FUQIANG YIN et al, 2014, Oncology Reports CrossRef - Methylation of SPARCL1 Is Associated with Oncologic Outcome of Advanced Upper Urinary Tract Urothelial Carcinoma
Hao-Lun Luo et al, 2019, International Journal of Molecular Sciences CrossRef - SPARCL1 Is a Novel Prognostic Biomarker and Correlates with Tumor Microenvironment in Colorectal Cancer
Hai-Ping Zhang et al, 2022, BioMed Research International CrossRef - Bibliometric and visualized analysis of drug resistance in ovarian cancer from 2013 to 2022
Jiahua Liu et al, 2023, Frontiers in Oncology CrossRef - Downregulation of NEK11 is associated with drug resistance in ovarian cancer
XIA LIU et al, 2014, International Journal of Oncology CrossRef - Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer
Yutao Gao et al, 2017, Oncology Reports CrossRef - Role of CC Chemokines Subfamily in the Platinum Drugs Resistance Promotion in Cancer
Maria E. Reyes et al, 2020, Frontiers in Immunology CrossRef - Associations of tumor suppressor SPARCL1 with cancer progression and prognosis
Ting Li et al, 2017, Oncology Letters CrossRef - Proteomic Analysis of Urine to Identify Breast Cancer Biomarker Candidates Using a Label-Free LC-MS/MS Approach
Julia Beretov et al, 2015, PLOS ONE CrossRef